{"id":2176,"date":"2026-03-22T05:04:02","date_gmt":"2026-03-22T05:04:02","guid":{"rendered":"https:\/\/hvthemesdemo.com\/aceso\/site\/?p=2176"},"modified":"2026-07-08T10:22:26","modified_gmt":"2026-07-08T10:22:26","slug":"satt-axlr-enters-the-capital-of-aceso-therapeutics-and-supports-the-development-of-act-101-for-cystic-fibrosis","status":"publish","type":"post","link":"https:\/\/hvthemesdemo.com\/aceso\/site\/satt-axlr-enters-the-capital-of-aceso-therapeutics-and-supports-the-development-of-act-101-for-cystic-fibrosis\/","title":{"rendered":"SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>SATT AxLR<\/strong> enters the capital of <strong>Aceso Therapeutics<\/strong> and supports the development of ACT-101 for cystic fibrosis<\/p>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Montpellier, March 2026 \u2014 Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for cystic fibrosis.<\/p>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">This support confirms the maturity of the <strong>ACT-101<\/strong> program, an <strong>antisense oligonucleotide (ASO)-based therapy<\/strong> currently in advanced preclinical development, with an <strong>IND filing planned for 2027<\/strong> (TRL 6).<\/p>\n<\/blockquote>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">After supporting the maturation of the project up to TRL 4, SATT AxLR confirms its commitment within the framework of this <strong>technology transfer<\/strong>, as well as its role in management and <strong>valorization<\/strong> on behalf of the relevant Montpellier research institutions, including the <strong>Universit\u00e9 de Montpellier, INSERM,<\/strong> and <strong>CNRS.<\/strong><\/p>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cystic fibrosis<\/strong> remains a rare genetic disease affecting more than <strong>110,000 patients worldwide<\/strong>, of whom approximately <strong>20% still have no effective therapeutic option<\/strong>. ACT-101 aims to address this unmet medical need by targeting the underlying genetic mechanisms of the disease.<\/p>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">This transaction is part of an innovation ecosystem supported by public research institutions, the <strong>Occitanie region<\/strong>, and <strong>Bpifrance<\/strong>, fostering technology transfer and value creation in the biotechnology sector.<\/p>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Contact press :<\/strong> <a href=\"mailto:contact@aceso-therapeutics.com\">contact@aceso-therapeutics.com<\/a><\/p>\n\n\n\n<div style=\"height:22px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Linkedin:<\/strong> <a href=\"https:\/\/www.linkedin.com\/company\/aceso-therapeutics\">https:\/\/www.linkedin.com\/company\/aceso-therapeutics<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montpellier, March 2026 \u2014 Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for cystic fibrosis.<\/p>\n","protected":false},"author":1,"featured_media":2586,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16],"tags":[],"class_list":["post-2176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/posts\/2176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/comments?post=2176"}],"version-history":[{"count":22,"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/posts\/2176\/revisions"}],"predecessor-version":[{"id":4440,"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/posts\/2176\/revisions\/4440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/media\/2586"}],"wp:attachment":[{"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/media?parent=2176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/categories?post=2176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hvthemesdemo.com\/aceso\/site\/wp-json\/wp\/v2\/tags?post=2176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}